Pamoja Capital

The Pamoja Capital Group is a private investment firm founded in 2006 by John McCall MacBain and his team following the sale of Trader Classified Media. Pamoja means “togetherness in Swahili. Pamoja Capital Group creates value through long-term, socially-responsible, global investments across a number of industry sectors, including education, life sciences, information technology, real estate and media and communications. The firm's investments span all stages of corporate growth, including seed and growth capital. The firm places special emphasis on investing in businesses with sustainable cash flow. Pamoja Capital Group believes that the experience of its managers in operating global businesses, combined with the long-term orientation of its financial resources, gives its portfolio companies a distinct competitive advantage.

Elton Forrest

Managing Director

Alexandra MacBain

Vice President

5 past transactions

Mindgram

Seed Round in 2022
Mindgram is a science-based platform and mobile app for complete mental wellness.

Mindgram

Pre Seed Round in 2021
Mindgram is a science-based platform and mobile app for complete mental wellness.

Talaris Therapeutics

Series B in 2020
Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

Vapogenix

Series C in 2016
Vapogenix is a clinical-stage company developing a new class of non-narcotic analgesics for localized pain. It focuses on treating pain locally at its source their products are formulated volatile anesthetics currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. It was founded in 2006 and headquartered in Houston, Texas.

Vapogenix

Series B in 2015
Vapogenix is a clinical-stage company developing a new class of non-narcotic analgesics for localized pain. It focuses on treating pain locally at its source their products are formulated volatile anesthetics currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. It was founded in 2006 and headquartered in Houston, Texas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.